Ipamorelin
A$299
Ipamorelin
Ipamorelin is a selective growth hormone releasing peptide (GHRP) that stimulates the pituitary gland to release growth hormone without significantly affecting cortisol or prolactin. It has been studied in the context of growth hormone optimisation, sleep quality and recovery support. Suitability varies according to individual health status, existing conditions and bloodwork.
Strength
5 mg
Volume
2 mL
Format
Dual-chamber pen
Administration
Subcutaneous injection
Storage
Refrigerated 2–8°C
Product code
IP5
Overview
Ipamorelin is a synthetic pentapeptide that mimics ghrelin and selectively binds to growth hormone secretagogue receptors in the pituitary gland, triggering pulsatile GH release without the appetite stimulation or cortisol elevation seen with some other secretagogues.
It has been studied in clinical settings involving growth hormone deficiency and recovery support. Individual responses vary considerably and depend on baseline hormone status, lifestyle factors and concurrent medications.
Ipamorelin is a compounded product supplied following assessment, bloodwork and practitioner review. This is not an approved indication for this peptide and individual outcomes cannot be guaranteed.
Commonly considered for
Growth hormone signalling
Acts through pituitary GH secretagogue receptors to support pulsatile GH release.
Recovery support
May be considered as part of a clinician-guided recovery protocol involving GH optimisation.
Sleep quality consideration
Has been studied in relation to sleep architecture and nocturnal GH secretion patterns.
Cortisol-sparing profile
Unlike some GHRPs, ipamorelin shows a selective action with minimal effect on ACTH and cortisol.
How it works
Signal
Ipamorelin binds to ghrelin receptors (GHS-R1a) in the anterior pituitary gland, mimicking the natural GH-releasing signal.
Response
The pituitary releases a pulse of growth hormone. This supports downstream IGF-1 production, tissue recovery and metabolic signalling.
Monitoring
IGF-1, fasting glucose and relevant hormone levels may be monitored to assess response and identify any need to adjust or discontinue.
Often stacked with
Suitability, cautions and safety
Important: This information is for educational purposes only. It does not replace assessment, diagnosis or medical advice from a qualified clinician. Suitability varies by individual health history, medications and circumstances.
Active or history of cancer
Growth hormone pathways may stimulate cell growth. Any personal or family history of cancer requires clinical review before use.
Diabetes or abnormal glucose
GH release can affect insulin sensitivity and blood glucose. Review with a clinician if you have diabetes or abnormal HbA1c.
Pituitary or endocrine disorders
Existing pituitary conditions or endocrine dysfunction require specialist assessment.
Pregnancy, breastfeeding or trying to conceive
Safety data is insufficient. Clinical guidance is required before use.
Competitive sport
GHRPs are prohibited in sport under WADA regulations. Review anti-doping obligations before use.
Planned or recent surgery
Discuss use with your treating clinician before any surgical procedure.
Fluid retention or joint symptoms
GH elevation can cause fluid retention, joint discomfort or carpal tunnel symptoms in some individuals.
Answer each question honestly. If you answer Yes to any question, we recommend discussing this compound with a qualified clinician before proceeding.
Do you currently have cancer, or have you been treated for cancer in the past?
Do you have diabetes or have you received abnormal blood sugar results?
Do you have a diagnosed pituitary condition or any other endocrine disorder?
Are you pregnant, breastfeeding or trying to conceive?
Are you subject to anti-doping testing in competitive sport?
Do you have surgery planned within the next 8 weeks?
Are you currently using another peptide, growth hormone or hormone-related treatment?
If you have any of the following, discuss with a clinician before purchasing or using this product
- Unexplained swelling of hands, feet or face
- Joint pain or wrist numbness
- Persistent severe headaches
- Vision changes
- Excessive thirst or frequent urination
- Unexplained fatigue
- Significant changes in mood or cognition
- Rapid or irregular heartbeat
Adverse effects and safety signals
Common effects
Generally mild and often resolve without intervention. Monitor and report if persistent.
- Injection-site redness or swelling — Usually mild and resolves quickly.
- Headache — Commonly reported during initial use.
- Fatigue or sleepiness — Particularly if administered at night.
- Nausea — Usually transient.
- Temporary fluid retention — Mild swelling, particularly in extremities.
Discuss promptly with a clinician
If any of the following occur, stop use and contact your prescribing practitioner.
- Persistent or worsening swelling — Discuss with a clinician if oedema does not resolve.
- Joint discomfort or carpal tunnel symptoms
- Significant glucose changes
- Repeated vomiting or severe nausea
- Unusual mood changes or cognitive symptoms
Seek emergency help immediately
If you experience any of the following, call emergency services (000 in Australia) immediately. These may be signs of a serious allergic reaction or medical emergency.
- Difficulty breathing or throat tightening
- Facial, lip or tongue swelling
- Widespread hives or rash
- Fainting or collapse
- Severe chest pain
Important: Before use, tell your practitioner if you have ever had an allergic reaction to any peptide, injection product or medicine. Allergic reactions can occur even with first use. I understand that I should seek urgent medical help if I experience signs of a serious allergic reaction.
Medications and interactions
Medicines and treatments to discuss
Ipamorelin may interact with insulin, diabetes medicines, other growth hormone-related compounds, glucocorticoids (steroids), thyroid medications and other peptides. Do not assume a product is irrelevant because it was purchased without a prescription. Disclose all prescription medicines, supplements, herbal products and recreational substances during your assessment.
Bloodwork and monitoring
The following tests may be considered at baseline and during use. Your Zenith practitioner will advise on what is relevant for you.
Baseline (before use)
- IGF-1
- Fasting glucose
- HbA1c
- Full blood count
- Thyroid function
Follow-up (during use)
- IGF-1
- Fasting glucose
Administration
Administer by subcutaneous injection into the abdomen, thigh or upper arm.
Rotate injection sites to reduce local tissue changes.
Commonly administered 2–3 times daily, including before sleep.
Follow the specific dosing and timing guidance provided with your protocol card.
Use a fresh needle for each injection and dispose of sharps safely.
Do not inject into irritated, bruised or infected skin.
Storage and handling
Store unopened pens refrigerated at 2–8°C.
Once activated, use within 28 days when stored refrigerated.
Do not freeze. Freezing may degrade the peptide.
Protect from direct light and heat.
Do not use if the solution appears cloudy, discoloured or contains particles.
Research context: Considered one of the safest GHRPs with the most selective GH-releasing action.
Frequently asked
Ipamorelin is a synthetic pentapeptide that selectively stimulates the pituitary gland to release growth hormone. It is considered one of the most selective GH secretagogues due to its minimal effect on cortisol and prolactin.
It is commonly discussed in the context of growth hormone optimisation, recovery support and sleep quality. Individual suitability and outcomes vary.
Relevant baseline testing — including IGF-1, fasting glucose and a hormone panel — can help identify risks and establish a starting point. All Zenith supply requires assessment and practitioner review.
It is commonly used alongside CJC-1295 No DAC for a synergistic GH pulse. Combinations should be discussed with your practitioner during the assessment.
Stop use and seek medical advice. If you experience difficulty breathing, throat swelling or collapse, call emergency services immediately.
No. GHRPs including ipamorelin are prohibited under WADA anti-doping regulations. Review your obligations before use.
Refrigerated at 2–8°C. Do not freeze. Use activated pens within 28 days.
Regulatory and classification note: Ipamorelin is a compounded peptide supplied as a prescription product following assessment and practitioner review. It is not TGA-approved for the indications described. Off-label and compounded use carries additional uncertainty. This information is educational and does not constitute medical advice.
Regulatory & safety information
Ipamorelin is supplied subject to suitability assessment and applicable UAE regulatory requirements. Information provided is general and is not a substitute for professional medical advice, diagnosis or treatment.
Always consult a qualified healthcare professional before starting, changing or stopping any product, particularly if you are pregnant, breastfeeding, under 18, or managing a medical condition.
Why treatment isn't self-selected
Treatment decisions need context.
Selecting a treatment option is the starting point. What's clinically appropriate for you is determined by three things together.
Your bloodwork
Relevant biomarkers help identify which treatment options may be appropriate — and which should be avoided.
Your health history
Existing conditions, medications and goals are considered alongside your results, not in isolation.
Practitioner review
A licensed practitioner reviews every request before anything is approved, dosed or supplied.
Before you choose
Your bloodwork can change the conversation.
Recent bloodwork gives your practitioner more to work with — helping identify what may be appropriate, what should be avoided, and where a different option might be better suited to your results.
Already uploaded results? Your practitioner reviews them alongside any treatment request — no need to repeat information.
Optional at this stage. Required before final approval.
Ready to move forward?
Three ways to continue.
Upload your bloodwork
Already have recent results? Upload them so your practitioner can review your treatment request in context.
Purchase a blood test
No recent results? Order an at-home Zenith blood test to establish your baseline before choosing treatment.
Start your assessment
Begin the health assessment now — you can add bloodwork and treatment selections at any stage.
Purchase
Ipamorelin
Supplied following assessment, bloodwork and practitioner review.
Price
A$299
Ready to start?
Complete an assessment and get access to Ipamorelin through a tailored protocol.